Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes

Habib Yaribeygi, Stephen Atkin, Amirhossein Sahebkar

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Diabetes mellitus prevalence is increasing worldwide leading to increased morbidity and mortality through diabetes related microvascular and macrovascular disease. The treatment of hypertension has been shown to be a major therapeutic intervention for the prevention of cardiovascular events and other diabetes related complications in diabetes. Sodium-glucose co-transporter inhibitors (SGLT2i) are newly introduced anti-diabetes drugs that lower blood glucose by the inhibition of glucose reuptake and the induction of glycosuria. However, there is increasing evidence showing their cardiovascular benefit beyond the improvement of glycemic control. Here we review the latest findings on the effect of SGLT2i on blood pressure in diabetes.

Original languageEnglish
Pages (from-to)1679-1683
Number of pages5
JournalDiabetes and Metabolic Syndrome: Clinical Research and Reviews
Volume13
Issue number2
DOIs
Publication statusPublished - 1 Mar 2019

Fingerprint

Sodium-Glucose Transport Proteins
Glycosuria
Symporters
Diabetes Complications
Blood Glucose
Diabetes Mellitus
Blood Pressure
Hypertension
Morbidity
Glucose
Mortality
Pharmaceutical Preparations
Therapeutics

Keywords

  • Diabetes mellitus
  • Hypertension
  • Oxidative stress
  • Sodium-glucose co-transporter inhibitors

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes. / Yaribeygi, Habib; Atkin, Stephen; Sahebkar, Amirhossein.

In: Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 13, No. 2, 01.03.2019, p. 1679-1683.

Research output: Contribution to journalReview article

@article{36154cb179634b2aa9f7f91ecbc6ccea,
title = "Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes",
abstract = "Diabetes mellitus prevalence is increasing worldwide leading to increased morbidity and mortality through diabetes related microvascular and macrovascular disease. The treatment of hypertension has been shown to be a major therapeutic intervention for the prevention of cardiovascular events and other diabetes related complications in diabetes. Sodium-glucose co-transporter inhibitors (SGLT2i) are newly introduced anti-diabetes drugs that lower blood glucose by the inhibition of glucose reuptake and the induction of glycosuria. However, there is increasing evidence showing their cardiovascular benefit beyond the improvement of glycemic control. Here we review the latest findings on the effect of SGLT2i on blood pressure in diabetes.",
keywords = "Diabetes mellitus, Hypertension, Oxidative stress, Sodium-glucose co-transporter inhibitors",
author = "Habib Yaribeygi and Stephen Atkin and Amirhossein Sahebkar",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.dsx.2019.03.031",
language = "English",
volume = "13",
pages = "1679--1683",
journal = "Diabetes and Metabolic Syndrome: Clinical Research and Reviews",
issn = "1871-4021",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes

AU - Yaribeygi, Habib

AU - Atkin, Stephen

AU - Sahebkar, Amirhossein

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Diabetes mellitus prevalence is increasing worldwide leading to increased morbidity and mortality through diabetes related microvascular and macrovascular disease. The treatment of hypertension has been shown to be a major therapeutic intervention for the prevention of cardiovascular events and other diabetes related complications in diabetes. Sodium-glucose co-transporter inhibitors (SGLT2i) are newly introduced anti-diabetes drugs that lower blood glucose by the inhibition of glucose reuptake and the induction of glycosuria. However, there is increasing evidence showing their cardiovascular benefit beyond the improvement of glycemic control. Here we review the latest findings on the effect of SGLT2i on blood pressure in diabetes.

AB - Diabetes mellitus prevalence is increasing worldwide leading to increased morbidity and mortality through diabetes related microvascular and macrovascular disease. The treatment of hypertension has been shown to be a major therapeutic intervention for the prevention of cardiovascular events and other diabetes related complications in diabetes. Sodium-glucose co-transporter inhibitors (SGLT2i) are newly introduced anti-diabetes drugs that lower blood glucose by the inhibition of glucose reuptake and the induction of glycosuria. However, there is increasing evidence showing their cardiovascular benefit beyond the improvement of glycemic control. Here we review the latest findings on the effect of SGLT2i on blood pressure in diabetes.

KW - Diabetes mellitus

KW - Hypertension

KW - Oxidative stress

KW - Sodium-glucose co-transporter inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85063156595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063156595&partnerID=8YFLogxK

U2 - 10.1016/j.dsx.2019.03.031

DO - 10.1016/j.dsx.2019.03.031

M3 - Review article

VL - 13

SP - 1679

EP - 1683

JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews

JF - Diabetes and Metabolic Syndrome: Clinical Research and Reviews

SN - 1871-4021

IS - 2

ER -